Bolt Biotherapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-2.97 | $-4.57 | -53.9% | Miss |
| Q12026 FY2026 | $-2.85 | $-4.31 | -51.2% | Miss |
| Q42025 FY2025 | $-4.27 | $-3.84 | +10.1% | Beat |
Back to BOLT overview · BOLT holders · BOLT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.